Avidity Biosciences (RNA) files to withdraw Common Stock listing from Nasdaq

Rhea-AI Filing Summary

Avidity Biosciences, Inc. notified the removal/withdrawal of its Common Stock from listing and registration on the Nasdaq Stock Market LLC.

The notice states Nasdaq and the issuer each complied with the applicable rules under 17 CFR 240.12d2-2 governing voluntary withdrawal and removal procedures.

Insights

Corporate Governance Specialist

Form 25 records a voluntary removal of the company's common stock from Nasdaq.

The filing indicates a procedural delisting/withdrawal action for the Common Stock, with both Nasdaq and the issuer affirming compliance with 17 CFR 240.12d2-2. The text frames the action as following the exchange's and issuer's rules rather than as an enforcement delisting.

Timing and post-withdrawal trading venue or shareholder impacts are not detailed in the excerpt; subsequent filings or disclosures may specify next steps and trading arrangements.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-39321

Issuer:	Avidity Biosciences, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	3020 Callan Rd.,
	San Diego	CALIFORNIA	92121
Telephone number:					858-401-7900

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-02-27	By	Tara Petta		Director
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 filed for Avidity Biosciences (RNA) announce?

It announces removal/withdrawal of the company's Common Stock from Nasdaq listing. The filing states both Nasdaq and the issuer complied with 17 CFR 240.12d2-2 governing voluntary withdrawal procedures.

Does the filing say whether the delisting was voluntary or involuntary for RNA?

The filing states the action follows rules for a voluntary withdrawal under 17 CFR 240.12d2-2, and that the issuer and Nasdaq complied with the applicable procedures.

Will Avidity Biosciences continue to trade after removal from Nasdaq?

The excerpt does not specify a replacement trading venue. It only logs withdrawal from Nasdaq and compliance with the exchange's voluntary withdrawal rules.

Who certified the removal for Avidity Biosciences on the Form 25?

Nasdaq Stock Market LLC certified it had reasonable grounds to file Form 25 and the notice was signed on Nasdaq’s behalf by an authorized person identified as Tara Petta, Director.

Which securities class is affected by this Form 25 for RNA?

The filing identifies the affected class as Common Stock, stating that Nasdaq has struck the class from listing and/or withdrawn its registration under the Exchange Act.